Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia

Emerging Infectious Diseases

Volumn 22, Issue 9, 2016, Pages 1554-1561

  Arabi, Yaseen M ^a   Hajeer, Ali H ^a   Luke, Thomas ^b   Raviprakash, Kanakatte ^b   Balkhy, Hanan ^a   Johani, Sameera ^a   Al Dawood, Abdulaziz ^a   Al Qahtani, Saad ^a   Al Omari, Awad ^c   Al Hameed, Fahad ^a   Hayden, Frederick G ^d   Fowler, Robert ^e   Bouchama, Abderrezak ^a   Shindo, Nahoko ^f   Al Khairy, Khalid ^a   Carson, Gail ^g   Taha, Yusri ^h   Sadat, Musharaf ^a   Alahmadi, Mashail ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h King Abdul Aziz Hospital   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONVALESCENT PLASMA IMMUNOTHERAPY; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEALTH CARE PERSONNEL; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; OUTCOME ASSESSMENT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAUDI ARABIA; SERODIAGNOSIS; CORONAVIRUS INFECTION; GENETICS; IMMUNOLOGY; PLASMA; PROCEDURES; VIROLOGY;

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS RNA;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEALTH PERSONNEL; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NEUTRALIZATION TESTS; PLASMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SAUDI ARABIA;

EID: 84988354790     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2209.151164     Document Type: Article

References (32)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20. http://dx.doi.org/10.1056/NEJMoa1211721
2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2016 Jun 26]. http://www.who.int/ emergencies/mers-cov/en/
3. Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health and Research Perspectives. 2015;6:269–78. http://dx.doi.org/10.1016/j.phrp.2015.08.006
4. Public Health England, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Treatment of MERS-CoV: information for clinicians. Clinical decision-making support for treatment of MERS-CoV patients. V3.0 [cited 2016 Apr 29]. http://www.gov.uk/government/uploads/system/uploads/ attachment_data/file/459835/merscov_for_clinicians_sept2015.pdf
5. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144:464–73. http://dx.doi.org/10.1378/chest.12-2907
6. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343. http://dx.doi.org/10.1371/journal.pmed.0030343
7. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–56. http://dx.doi.org/10.1093/cid/ciq106
8. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–609. http://dx.doi.org/10.7326/0003-4819-145-8-200610170-00139
9. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–6. http://dx.doi.org/10.1007/s10096-004-1271-9
10. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006;12:489.
11. Mair-Jenkins J, Saavedra-Campos M, Baillie K, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. http://dx.doi.org/10.1093/infdis/jiu396
12. Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol. 2015;89:6117–20. http://dx.doi.org/10.1128/JVI.00446-15
13. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4:709. http://dx.doi.org/10.1186/s40064-015-1490-9
14. Centers for Disease Control and Prevention. CDC laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2015 Sep 22]. http://www.cdc.gov/coronavirus/ MERS/lab/lab-testing.html
15. World Health Organization. Laboratory testing for Middle East respiratory syndrome coronavirus: interim recommendations (revised); September 2014 [cited 2015 Sep 22]. http://www.who.int/ csr/disease/coronavirus_infections/WHO_interim_recommendations_ lab_detection_MERSCoV_092014.pdf
16. Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016;8:326ra21. http://dx.doi.org/10.1126/scitranslmed.aaf1061
17. World Health Organization. Guidelines on assessing donor suitability for blood donation [cited 2015 Sep 22]. http://apps.who.int/iris/bitstream/10665/76724/1/9789241548519_ eng.pdf?ua=1
18. WHO Blood Regulators Network (BRN). Position paper on collection and use of convalescent plasma or serum as an element in Middle East respiratory syndrome coronavirus response [cited 2015 Sep 22]. http://www.who.int/bloodproducts/brn/BRN_ PositionPaperConvPlasmaMERSCoV_March2014.pdf
19. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. 2012;17:20285.
20. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371:828–35. http://dx.doi.org/10.1056/NEJMoa1405858
21. Müller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15:559–64. http://dx.doi.org/10.1016/S1473-3099(15)70090-3
22. Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol. 2013;87:9379–83. http://dx.doi.org/10.1128/JVI.01277-13
23. Chu DK, Poon LL, Gomaa MM, Shehata MM, Perera RA, Abu Zeid D, et al. MERS coronaviruses in dromedary camels, Egypt. Emerg Infect Dis. 2014;20:1049–53. http://dx.doi.org/10.3201/eid2006.140299
24. Gierer S, Hofmann-Winkler H, Albuali WH, Bertram S, Al-Rubaish AM, Yousef AA, et al. Lack of MERS coronavirus neutralizing antibodies in humans, Eastern Province, Saudi Arabia. Emerg Infect Dis. 2013;19:2034–6. http://dx.doi.org/10.3201/ eid1912.130701
25. Aburizaiza AS, Mattes FM, Azhar EI, Hassan AM, Memish ZA, Muth D, et al. Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. J Infect Dis. 2014;209:243–6. http://dx.doi.org/10.1093/infdis/jit589
26. Memish ZA, Alsahly A, Masri MA, Heil GL, Anderson BD, Peiris M, et al. Sparse evidence of MERS-CoV infection among animal workers living in southern Saudi Arabia during 2012. Influenza Other Respir Viruses. 2015;9:64–7. http://dx.doi.org/10.1111/ irv.12287
27. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357:1162–3. http://dx.doi.org/10.1056/ NEJMc070348
28. Xie L, Liu Y, Fan B, Xiao Y, Tian Q, Chen L, et al. Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respir Res. 2005;6:5. http://dx.doi.org/10.1186/1465-9921-6-5
29. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105:435–46. http://dx.doi.org/10.1017/S0950268800048019
30. Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC, Burbelo PD, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio. 2014;5:e00884-14. http://dx.doi.org/10.1128/mBio.01002-14
31. The Wall Street Journal. South Korea tries old weapon to fight MERS [cited 2015 Sep 22]. http://www.wsj.com/articles/south-korea-tries-old-weapon-to-fight-mers-1434451587
32. Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, et al. Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2015;112:8738–43. http://dx.doi.org/10.1073/pnas.1510830112